Any current/future new fundraising through debt or equity?

There is no mention of any current or future fundraising through debt or equity in the transcript. The company is maintaining a strong cash position with approximately INR 200 crores in surplus cash and treasury balance. Capex plans for the next 1 to 1.5 years, including 12-14 new hub centers and a renovation project, are planned within an INR 200 crore budget funded internally. The company is focusing on strategic expansion and capital allocation without indicating any need for additional external funding. PET-CT equipment was acquired on a pay-per-use model to optimize capital allocation, in

Any current/future capex/capital investment/strategic investment?

The company has budgeted INR 200 crores capex for commissioning 12 new hub centers over FY '25 and '26. This INR 200 crores capex includes renovation and addition of extra MRI at Kurnool. Additional two hub centers in Andhra Pradesh and Telangana are planned, with leases under finalization, expected by Q3 FY '26. Capex plans remain materially unchanged despite new hubs and PET-CT machine in Tirupathi. PET-CT at Tirupathi is on a pay-per-use model, thus not part of capex. Focus on strategic expansion across Bangalore, Pune, Kolkata, and adjacent geographies. Investments continue in IT systems a

Future growth expectations in sales/revenue/volumes?

The company targets a 15% compound annual growth rate (CAGR) over the next 3 years. Expected volume growth is around 13% per year, with the remaining revenue growth attributed to value or realization growth of approximately 2%. Growth outlook includes significant hub expansion: 12 hubs planned over 1.5 years, including new geographies like Bangalore, Pune, and Kolkata. New hubs are expected to take about 1 year to achieve EBITDA breakeven. Market share gains are expected in core geographies (Andhra Pradesh and Telangana) due to brand strength, dense network, and advanced technology. Wellness s

Future growth expectations in earnings/operating earnings/profits/EPS?

The company targets a 15% CAGR growth over the next 3 years, driven primarily by ~13% volume growth and 2% realization growth, resulting in mid-teens overall revenue growth. Plans to add around 12-14 new hub centers across FY '25 and FY '26 to fuel growth, including expansion into new geographies like Bengaluru, Pune, and Kolkata. EBITDA margins expected to remain around 40%, with a possible 1-2% short-term dip when multiple hubs open simultaneously; EBITDA breakeven in new hubs anticipated within 1 year. Pre-IndAS EBITDA margins were around 33.5%, currently 40% under IndAS due to rent t

IN US

Sale is live|00:00:00left today

Vijaya Diagnostic Centre LtdQ4 FY26Healthcare Services

Vijaya Diagnostic Centre Ltd Q4 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,288P/E: 79.1Market Cap: ₹13.7K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→The company targets a 15% compound annual growth rate (CAGR) over the next 3 years.
→Expected volume growth is around 13% per year, with the remaining revenue growth attributed to value or realization growth of approximately 2%.
→Growth outlook includes significant hub expansion: 12 hubs planned over 1.5 years, including new geographies like Bangalore, Pune, and Kolkata.
→New hubs are expected to take about 1 year to achieve EBITDA breakeven.
→Market share gains are expected in core geographies (Andhra Pradesh and Telangana) due to brand strength, dense network, and advanced technology.
→Wellness segment growth remains strong, contributing about 14% to the top line, with potential seasonal Q4 benefits.
→The company's conservative guidance aims to overachieve actual growth, with potential upside from new hub additions and market expansion.

Margin guidance

Category 3

→The company targets a 15% CAGR growth over the next 3 years, driven primarily by ~13% volume growth and 2% realization growth, resulting in mid-teens overall revenue growth.
→Plans to add around 12-14 new hub centers across FY '25 and FY '26 to fuel growth, including expansion into new geographies like Bengaluru, Pune, and Kolkata.
→EBITDA margins expected to remain around 40%, with a possible 1-2% short-term dip when multiple hubs open simultaneously; EBITDA breakeven in new hubs anticipated within 1 year.
→Pre-IndAS EBITDA margins were around 33.5%, currently 40% under IndAS due to rent treatment, indicating underlying margin strength.
→PAT margins currently near 21%, with an expected ~1% positive impact adjusting for pre-IndAS.
→Operating leverage seen in 3-4% range typically, but near term growth investments and GST impact (~0.3%) might moderate margin expansion.
→Long term margin expansion expected post stabilization and densification of new hubs and markets.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no mention of any current or future fundraising through debt or equity in the transcript.
→The company is maintaining a strong cash position with approximately INR 200 crores in surplus cash and treasury balance.
→Capex plans for the next 1 to 1.5 years, including 12-14 new hub centers and a renovation project, are planned within an INR 200 crore budget funded internally.
→The company is focusing on strategic expansion and capital allocation without indicating any need for additional external funding.
→PET-CT equipment was acquired on a pay-per-use model to optimize capital allocation, indicating a preference for internal capital efficiency rather than new debt or equity.
→Overall, the company appears well-capitalized to meet its growth plans without requiring fundraising at this time.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders for Vijaya Diagnostic Centre Limited. However, some related operational insights include: - The company is on track to commission 9 new hub centers in the next 6 months, following 3 already commissioned in the 9-month period ended December 2024. - Additional leases are under finalization in Andhra Pradesh and Telangana, with civil works expected to start after lease execution. - The company plans to add approximately 12 to 14 new hubs across FY '25 and FY '26 in multiple geographies including Bangalore, Pune, Kolkata, AP, and Telangana. - There is a significant focus on densifying networks and expanding in core and new geographies, indicating a strong pipeline of growth and expansion projects. No direct quantitative details on order books or pending orders are disclosed in the call transcript.

Capex plans

Yes

→The company has budgeted INR 200 crores capex for commissioning 12 new hub centers over FY '25 and '26.
→This INR 200 crores capex includes renovation and addition of extra MRI at Kurnool.
→Additional two hub centers in Andhra Pradesh and Telangana are planned, with leases under finalization, expected by Q3 FY '26.
→Capex plans remain materially unchanged despite new hubs and PET-CT machine in Tirupathi.
→PET-CT at Tirupathi is on a pay-per-use model, thus not part of capex.
→Focus on strategic expansion across Bangalore, Pune, Kolkata, and adjacent geographies.
→Investments continue in IT systems and CRM to enhance customer experience and operational efficiency.
→Capex strategy supports ability to rapidly expand and densify network beyond core geographies.

How does Vijaya Diagnostic Centre Ltd rank vs peers in Healthcare Services?

Pro feature

1Vijaya Diagnostic Centre Ltd

Rev 3Mar 3

See full Healthcare Services sector rankings

Want more stocks like Vijaya Diagnostic Centre Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio